Teriparatide (PTH 1-34)
Teriparatide is the recombinant PTH(1-34) N-terminal fragment. FDA-approved for osteoporosis, it's the most potent bone-building drug available. Intermittent daily dosing preferentially stimulates osteoblast activity over osteoclast-driven resorption.
Community Rating
No ratings yet
Compound Profile
Teriparatide (PTH 1-34)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Teriparatide (PTH 1-34) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Most potent anabolic bone agent available — FDA-approved for severe osteoporosis with fracture risk
- Increases bone mineral density (BMD) by 8-13% at lumbar spine and 2-5% at hip over 18-24 months
- Reduces vertebral fracture risk by approximately 65% vs placebo (FPT trial)
- Teriparatide (PTH 1-34) is not FDA-approved for human use. FDA-approved prescription drug (Forteo, Eli Lilly; Movymia, biosimilar). Controlled by REMS program due to osteosarcoma risk concern in rodents.
Research At a Glance
- Most potent anabolic bone agent available — FDA-approved for severe osteoporosis with fracture risk
- Increases bone mineral density (BMD) by 8-13% at lumbar spine and 2-5% at hip over 18-24 months
- Reduces vertebral fracture risk by approximately 65% vs placebo (FPT trial)
- Reduces non-vertebral fracture risk by approximately 35% (FPT trial)
In Plain English
Simple summaryTeriparatide (Forteo) is a synthetic version of the first 34 amino acids of parathyroid hormone (PTH) and is the only anabolic (bone-building) treatment for osteoporosis -- every other osteoporosis drug is antiresorptive (it slows bone loss rather than building new bone). This distinction matters enormously. When you give teriparatide as daily subcutaneous injections, it mimics the anabolic effect of naturally pulsatile PTH on osteoblasts (bone-building cells), stimulating new bone formation. Clinical trials showed it increased lumbar spine bone mineral density by 9% and reduced vertebral fracture risk by 65% over 18-21 months. FDA-approved in 2002, it remains one of the most effective pharmacological interventions for osteoporosis.
- Most potent anabolic bone agent available — FDA-approved for severe osteoporosis with fracture risk
- Increases bone mineral density (BMD) by 8-13% at lumbar spine and 2-5% at hip over 18-24 months
- Reduces vertebral fracture risk by approximately 65% vs placebo (FPT trial)
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Teriparatide (PTH 1-34)?
Tap any underlined term for an instant definition.
Teriparatide (brand name: Forteo) is recombinant human parathyroid hormone(1-34), comprising the biologically active N-terminal 34-amino acid fragment of the full 84-amino acid PTH molecule. It was FDA-approved in 2002 as the first anabolic treatment for osteoporosis — a therapeutic category that had previously been limited to antiresorptive drugs (bisphosphonates, SERMs, calcitonin).
PTH is the primary regulator of calcium homeostasis. Continuous PTH elevation (as in hyperparathyroidism) causes bone resorption. However, **intermittent PTH administration paradoxically stimulates bone formation** — a phenomenon first observed in the 1980s and now the pharmacological basis of teriparatide.
**The PTH1R and bone anabolic signaling:** PTH1R (PTH/PTHrP receptor, type 1) is a GPCR that activates both Gs (cAMP/PKA) and Gq (PLC/PKC) pathways. In osteoblasts, intermittent PTH1R activation: 1. Stimulates Wnt signaling via LRP5/6 → promotes osteoblastogenesis 2. Reduces SOST (sclerostin) production by osteocytes → removes inhibition of Wnt 3. Decreases RANKL/OPG ratio → transiently reduces osteoclast activity 4. Inhibits osteoblast apoptosis via PKA/Bcl-2 → increases functional osteoblast numbers 5. Net result: bone formation > bone resorption → increased BMD and improved microarchitecture
The FRACTURE Prevention Trial (Black et al., NEJM 2001) demonstrated 65% reduction in vertebral fractures and 35% reduction in non-vertebral fractures over 18 months in postmenopausal women with established osteoporosis.
Teriparatide is used in research for: stress fracture healing (proposed off-label), peri-implant bone augmentation in dentistry, investigation of PTH1R signaling in bone biology, and as a comparator for next-generation bone anabolic drugs (abaloparatide, romosozumab).
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Teriparatide (PTH 1-34). See all Muscle & Performance peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Teriparatide (Forteo/Movymia) is dosed once daily by subcutaneous injection:
Approved dose: 20 mcg SC once daily Duration: Maximum 24 months lifetime (due to theoretical osteosarcoma risk — since risk seen in Fischer 344 rats at supraphysiological doses) Injection site: Thigh or abdomen, rotating sites Post-treatment: Follow with antiresorptive therapy (bisphosphonate or denosumab) to consolidate bone gains
Orthopedic research protocols: Used off-label for stress fracture healing and peri-implant bone augmentation at similar doses
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Inject subcutaneously in the abdomen or thigh. Use the prefilled pen device. Can be administered at any time of day, but avoid bedtime if orthostatic hypotension is a concern. Refrigerate the pen; do not freeze.
What the research doesn't show
Teriparatide has a black box warning for osteosarcoma risk in rodents -- high-dose, long-duration animal studies showed bone tumors. The FDA limits treatment to 2 years and contraindicated it in people with elevated bone turnover markers, prior radiation, or Paget's disease. The osteosarcoma signal has not appeared in the human clinical or post-marketing record over 20+ years, but the warning is maintained due to the animal data.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Teriparatide (PTH 1-34), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Teriparatide (PTH 1-34) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: most potent anabolic bone agent available — fda-approved for severe osteoporosis with fracture risk.
The most commonly reported side effect in research subjects is nausea, leg cramps, and dizziness — common in first weeks; usually transient. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Abaloparatide (Tymlos) is a PTHrP analogue with similar anabolic effects and slightly different receptor binding -- approved in 2017. Romosozumab (Evenity) is a monoclonal antibody (not a peptide) that inhibits sclerostin and produces dramatic bone gains but has cardiovascular contraindications. Bisphosphonates (alendronate, zoledronate) are antiresorptive rather than anabolic. Teriparatide is given first when bone-building is the priority, often followed by antiresorptive consolidation.
Compare Teriparatide (PTH 1-34) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.